Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.

Expert review of molecular diagnostics - 1 Jan 2016

Diekstra Meta H M, Swen Jesse J, Gelderblom Hans, Guchelaar Henk-Jan

Abstract excerpt

OBJECTIVE: The individual response to targeted tyrosine kinase inhibitors (TKIs) in the treatment of metastatic renal cell cancer (mRCC) is highly variable. Outlined in this article are findings on potential biomarkers for TKI treatment outcome in mRCC and an evaluation of the status of clinical implementation. METHODS: Articles were selected by two independent reviewers using a systematic search in five medical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Pharmacological
Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Niacinamide

Share to Phenylurea Compounds

Share to Pyrroles

Share to Sorafenib

Share to Sunitinib

Source

Identifiers

PMID: 26837796
DOI: 10.1586/14737159.2016.1148601

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.PMID 26837796Read ↗

The role of pharmacogenomics in metastatic renal cell carcinoma.Semantic proximity Read ↗

Potential role of genetic markers in the management of kidney cancer.Semantic proximity Read ↗

Kidney cancer pathology in the new context of targeted therapy.Semantic proximity Read ↗

[Biomarkers of response to molecular targeted therapy in renal cell carcinoma].Semantic proximity Read ↗

Renal cell carcinoma.Semantic proximity Read ↗

EGFR pharmacogenomics: the story continues to mutate and evolve.Semantic proximity Read ↗

Therapeutic Guide for mTOuRing through the Braided Kidney Cancer Genomic River.Semantic proximity Read ↗

Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomesSemantic proximity Read ↗

Molecular biomarkers in advanced renal cell carcinoma.Semantic proximity Read ↗

Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenesSemantic proximity Read ↗

Distinct Molecular Profiles and Drug Vulnerabilities in Pancreatic Metastases of Renal Cell CarcinomaSemantic proximity Read ↗

Pharmacogenomic biomarkers for personalized cancer treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.